Table II.

Quarterly health‐related quality of life (HRQoL) completion rates through to 12 months.

n/N (%)*	EQ‐5D overall index
	RVd (n = 445)	VMP (n = 77)	Vd/VMP (n = 588)
Baseline	369/445 (82·9)	66/77 (85·7)	491/588 (83·5)
Q1	367/439 (83·6)	65/77 (84·4)	471/577 (81·6)
Q2	295/407 (72·5)	59/70 (84·3)	375/514 (73·0)
Q3	266/378 (70·4)	47/64 (73·4)	345/471 (73·2)
Q4	258/363 (71·1)	47/59 (79·7)	297/445 (66·7)

RVd, lenalidomide‐bortezomib‐dexamethasone; Vd, bortezomib‐dexamethasone; VMP, bortezomib‐melphalan‐prednisone.

^*Completion rates were defined as five/five questions answered.